Evidence map›Paper›PMID 41917392›Full record

ReviewAdvances in experimental medicine and biology2026

Glycan Structures of Human Immunoglobulins and Their Roles.

Noriko Suzuki

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Noriko SuzukiGraduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan. nrsuzuki@chiba-u.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunoglobulins (Igs) are antibodies that specifically recognize foreign bodies and induce immune responses. Among the five classes of Igs in humans, IgG, IgA, IgM, IgD, and IgE, human IgG is one of the most intensively studied glycoproteins because of its central role in the immune system as a major serum antibody and its effectiveness in clinical applications. The three-dimensional structures of human IgG with glycosylation suggest that subtle differences in glycan structures affect the protein structure of IgG, leading to significant differences in immune responses. To generate more effective antibody medicines, glycoengineering techniques have recently made it possible to manipulate antibodies with only specified N-glycan structures on the Fc region of IgG. In addition to the human IgG, the glycan structures and site occupancies at glycosylation sites on other Ig classes have also been investigated in detail by glycomics/glycoproteomics analysis using mass spectrometry. Human IgA and IgM are also expected to be used as therapeutic antibodies due to their unique properties and functions in the immune system. Site-specific glycan structures on IgD and IgE from a single donor can be analyzed using highly sensitive glycoproteomics, regardless of their relatively small amount in human serum. Although N-glycans of each Ig class often have similar structures, the degree of their contributions to the interaction with Fc receptors varies among the classes.

Indexed as

ImmunoglobulinsPolysaccharidesAnimalsGlycomicsGlycosylationHumansImmunoglobulinsPolysaccharidesBio-parameterGlycoengineeringGlycomicsGlycoproteomicsN-glycanO-glycanTherapeutic antibody

Identifiers

PMID41917392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.